1 brand tagged as Egfr Inhibitor. Discover which parent companies own these brands.
Owned by Roche
Roche's first-generation EGFR tyrosine kinase inhibitor (erlotinib) co-developed by Genentech and OSI Pharmaceuticals, FDA approved November 18, 2004, for EGFR-mutant non-small cell lung cancer and pancreatic cancer, with the branded product now discontinued as generic erlotinib is widely available.
